NCT07512908

Brief Summary

Clostridioides difficile (formerly C. difficile) is a bacterium found in the form of spores (a resistant form) to which patients may be exposed in a hospital environment. Once ingested, the spore can germinate in the digestive tract in its vegetative form (active form of the bacterium) and then takes on the appearance of a Gram-positive bacillus that colonizes the digestive microbiota. This preliminary stage of digestive colonization by the bacterium is facilitated by certain factors, in particular exposure to antibiotics, which disrupt the composition of the digestive microbiota (dysbiosis) and thus facilitate the establishment of C. difficile following the removal of the barrier effect of the digestive microbiota. Certain strains (known as "toxinogenic") are then able to produce the main virulence factors (toxins A (TcdA) and B (TcdB)), thereby causing the main clinical signs of digestive infection, particularly in patients with risk factors for C. difficile infection (elderly people, progressive cancer, immunodepression, etc.).The treatment of CDI is mainly based on the oral administration of anti-Clostridioides difficile antibiotics such as Fidaxomicin (FDX) or Vancomycin (VAN) for a period of 10 days, according to the European recommendations of the ESCMID and the American recommendations of the IDSA. Despite effective treatment, CDI is characterized by a high recurrence rate of up to 25% of cases, with multiple recurrences that can be particularly debilitating for patients. The effect of disruption of the gut microbiota (dysbiosis) following exposure to antibiotics can be explained by several non-exclusive hypotheses, such as the disappearance of protective bacterial species in the gut microbiota or, conversely, the appearance of bacterial species that favor the colonization of C. difficile. Hospitalization, and more generally healthcare, has often been identified as a risk factor for CDI.Indeed, C. difficile is found ubiquitously in the environment and contaminates food products. It is still difficult to assess the frequency of contamination through the ingestion of contaminated food and the potential colonization of the host. Only the composition of the gut microbiota appears to be an interesting avenue to explore, especially since it changes significantly during the first year of life as important events occur, including dietary diversification with the introduction of the first solid foods.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P75+ for not_applicable

Timeline
44mo left

Started May 2026

Longer than P75 for not_applicable

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 27, 2026

Completed
10 days until next milestone

First Posted

Study publicly available on registry

April 6, 2026

Completed
2 months until next milestone

Study Start

First participant enrolled

May 30, 2026

Expected
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 31, 2029

7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2029

Last Updated

April 13, 2026

Status Verified

August 1, 2025

Enrollment Period

3 years

First QC Date

March 27, 2026

Last Update Submit

April 7, 2026

Conditions

Keywords

characterize the kinetics of digestive colonization and decolonization (clearance) by C. difficile

Outcome Measures

Primary Outcomes (1)

  • characterize the kinetics of digestive colonization and decolonization (clearance) by C. difficile in infants

    characterize the kinetics of digestive colonization and decolonization (clearance) by C. difficile in infants from birth to 18 months of age.

    18 months

Study Arms (1)

cohort follow-up

OTHER

The only intervention will be in women with a vaginal swab. For children, stool samples will be collected at specific points.

Other: cohort follow up

Interventions

The only intervention will be in women with a vaginal swab. For children, stool samples will be collected at specific points.

cohort follow-up

Eligibility Criteria

Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
For mothers * Women aged 18 or over who are pregnant * Patients who have been informed and have consented to participate in the research * Patient affiliated with a health insurance plan (beneficiary or dependent), For minor patients (children) * unborn child * at least one parent of the child included is French-speaking * written consent from both parents for participation in the study criteria for non-inclusion parents under guardianship or trusteeship parents deprived of their liberty parents under judicial protection children born under X/or in foster care

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
SINGLE GROUP
Model Details: cohort study
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 27, 2026

First Posted

April 6, 2026

Study Start (Estimated)

May 30, 2026

Primary Completion (Estimated)

May 31, 2029

Study Completion (Estimated)

December 31, 2029

Last Updated

April 13, 2026

Record last verified: 2025-08